#1 Clinical Trials Search in Europe

Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)

This article discusses the use of drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) in clinical trials for advanced prostate cancer. These trials aim to evaluate the safety, efficacy, and potential benefits of combining these medications with other treatments for patients with metastatic castration-resistant prostate cancer (mCRPC). The research focuses on exploring new treatment options and improving outcomes for patients with this challenging form of cancer.

Table of Contents

Introduction to GORD Medications

Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) are a group of medications designed to treat conditions affecting the upper digestive system. These medications play a crucial role in managing symptoms and promoting healing in patients suffering from various gastrointestinal disorders.[1]

What Are Drugs for Peptic Ulcer and GORD?

Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) are a class of medications specifically formulated to address issues in the stomach and esophagus. These drugs work by reducing acid production in the stomach or protecting the lining of the digestive tract.[1]

Conditions Treated

While the primary focus of these medications is on peptic ulcers and GORD, they may also be used to treat or manage other related conditions. Some of the main conditions these drugs address include:

  • Peptic Ulcers: Open sores that develop on the inside lining of the stomach and the upper portion of the small intestine.
  • Gastro-oesophageal Reflux Disease (GORD): A chronic condition where stomach acid frequently flows back into the esophagus, causing irritation and discomfort.
  • Acid Reflux: A common condition where stomach acid flows back into the esophagus, causing heartburn and other symptoms.
  • Erosive Esophagitis: Inflammation and damage to the lining of the esophagus caused by stomach acid.

How These Drugs Are Administered

According to the clinical trial information, these drugs can be administered through various routes. One mentioned method is antegrade epicardial coronary artery infusion.[1] However, it’s important to note that this is an unusual route for GORD medications and may be specific to the research context. More common routes of administration for GORD drugs include:

  • Oral tablets or capsules
  • Liquid formulations
  • Intravenous injections (in hospital settings)

The specific route of administration will depend on the particular drug, the severity of the condition, and the patient’s individual needs.

Current Research and Clinical Trials

While the clinical trial data provided doesn’t specifically focus on GORD medications, it’s worth noting that research in this field is ongoing. Clinical trials often explore new formulations, combinations, or applications of existing drugs to improve treatment outcomes for patients with gastrointestinal disorders.[1]

Important Considerations for Patients

When taking drugs for peptic ulcer and GORD, patients should keep the following in mind:

  1. Follow prescribed dosage: Always take the medication as directed by your healthcare provider.
  2. Be aware of potential side effects: While generally well-tolerated, these drugs may cause side effects in some patients.
  3. Inform your doctor about other medications: Some GORD drugs may interact with other medications.
  4. Lifestyle modifications: In addition to medication, lifestyle changes such as dietary adjustments and weight management may be recommended.
  5. Regular follow-ups: Maintain regular check-ups with your healthcare provider to monitor your condition and adjust treatment if necessary.

Remember, while drugs for peptic ulcer and GORD can be highly effective in managing symptoms and promoting healing, they should always be used under the guidance of a healthcare professional. If you have any concerns or questions about your medication, don’t hesitate to consult with your doctor or pharmacist.

Aspect Details
Study Type Phase 1/2 Umbrella Substudy
Target Condition Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Main Objectives Evaluate safety, tolerability, and establish RP2D; Estimate PSA response rate
Key Inclusion Criteria Confirmed mCRPC, prior NHA treatment, evidence of disease progression
Key Exclusion Criteria Active CNS metastases, unstable cardiovascular disease, active autoimmune disease
Primary Endpoints DLTs, AEs, treatment discontinuation due to AEs, PSA response rate
Secondary Endpoints ORR, rPFS, OS, DOR, TFST, TTPP
Drug Category Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (GORD)
Administration Route Antegrade Epicardial Coronary Artery Infusion

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to evaluate the safety, tolerability, and efficacy of treatment combinations that include drugs for peptic ulcer and GORD in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial aims to establish the recommended Phase 2 dose (RP2D) and assess the prostate-specific antigen (PSA) response rate for each treatment arm.
  • Who is eligible to participate in this clinical trial? Eligible participants include those with a confirmed diagnosis of adenocarcinoma of the prostate without small cell histology, evidence of metastatic disease, and prior treatment with 1 to 2 novel hormonal agents (NHAs). Patients must have experienced disease progression during or after treatment and meet specific criteria regarding previous therapies and overall health status.
  • What are some of the exclusion criteria for this trial? Some exclusion criteria include a history of pituitary dysfunction, active autoimmune disease requiring systemic treatment in the past 2 years, active infections requiring systemic therapy, poorly controlled diabetes mellitus, and active or unstable cardiovascular or cerebrovascular disease. Patients with known active central nervous system metastases or additional progressing malignancies are also excluded.
  • What are the primary endpoints of the study? The primary endpoints of the study include the number of participants experiencing dose-limiting toxicities (DLTs) or adverse events (AEs), the number of participants who discontinue the study intervention due to an AE, and the prostate-specific antigen (PSA) response rate.
  • How does this trial incorporate drugs for peptic ulcer and GORD? The trial incorporates drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) as part of the treatment combinations being studied. These drugs are classified under the ATC code A02B and are being evaluated alongside other cancer therapies to assess their potential benefits in treating advanced prostate cancer.

Ongoing Clinical Trials on Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)

  • Study of Opevesostat, Olaparib, and Cabazitaxel in Patients with Advanced Prostate Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark Finland France Germany Ireland Italy +2

Glossary

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC): A type of advanced prostate cancer that has spread to other parts of the body and continues to grow despite treatments that lower testosterone levels.
  • Prostate-Specific Antigen (PSA): A protein produced by the prostate gland. Elevated levels in the blood can indicate prostate cancer or other prostate conditions.
  • Novel Hormonal Agent (NHA): A type of medication used to treat prostate cancer by targeting hormones that fuel cancer growth.
  • Androgen Deprivation Therapy (ADT): A treatment that reduces levels of male hormones (androgens) to slow the growth of prostate cancer.
  • Dose-Limiting Toxicity (DLT): Side effects of a treatment that are severe enough to prevent an increase in dosage or require a reduction in dosage.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug determined to be safe and effective for further testing in larger clinical trials.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Radiographic Progression-Free Survival (rPFS): The length of time during and after treatment that a patient lives without cancer growth as seen on imaging scans.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Duration of Response (DOR): The length of time that a tumor continues to respond to treatment without growing or spreading.

References

  1. http://clinicaltrials.eu/trial/study-of-opevesostat-olaparib-and-cabazitaxel-in-patients-with-advanced-prostate-cancer/